News and reporting on colorectal cancer.
The firm believes that data from a recently published study illustrates the advantages of its technology for methylation-specific PCR assays.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.
CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.
In PLOS this week: links between placental transcriptome and weight; colorectal cancer-related microRNAs; and more.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
The team will combine CellMax's circulating tumor cell platform and Medigen's liquid biopsy panel to track treatment response in colorectal cancer patients.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.